{
  "company": {
    "name": "Combotope Therapeutics",
    "website": "https://combotopetherapeutics.com/",
    "record": "https://startuphistory.org/c/combotopetherapeutics.com"
  },
  "status": null,
  "history_since": "2023-10-07T18:55:39.000Z",
  "baseline": {
    "snapshot_id": "88c4a3d8a91d9004a39d3a4a017fd586fada9a5c37fd0e7a755d4cbd021abd56",
    "observed_at": "2023-10-07T18:55:39.000Z",
    "headline": "EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (",
    "description": null,
    "evidence": "https://web.archive.org/web/20231007185539/https://www.combotopetherapeutics.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-05T12:52:35.274Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2024-09-05T07:12:53.000Z",
      "variants": [
        {
          "headline": "EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (",
          "subhead": null,
          "observed_at": "2023-10-07T18:55:39.000Z",
          "evidence": "https://web.archive.org/web/20231007185539/https://www.combotopetherapeutics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (",
          "subhead": null,
          "observed_at": "2024-06-12T17:00:08.000Z",
          "evidence": "https://web.archive.org/web/20240612170008/https://www.combotopetherapeutics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (",
          "subhead": null,
          "observed_at": "2024-09-05T07:12:53.000Z",
          "evidence": "https://web.archive.org/web/20240905071253/https://www.combotopetherapeutics.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), CD133, CD90, CD326, Cripto-1, ABCG2, CD24, CD49, Notch2, CD146 (",
      "subhead": null,
      "from": "2023-10-07T18:55:39.000Z",
      "to": "2024-09-05T07:12:53.000Z",
      "captures": 3,
      "evidence": "https://web.archive.org/web/20240905071253/https://www.combotopetherapeutics.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2023-10-07T18:55:39.000Z",
          "to": "2024-09-05T07:12:53.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2025-03-31T00:18:12.000Z",
      "variants": [
        {
          "headline": "Truly Tumor-Specific antibodies",
          "subhead": null,
          "observed_at": "2025-02-06T18:43:12.000Z",
          "evidence": "https://web.archive.org/web/20250206184312/https://www.combotopetherapeutics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Truly Tumor-Specific antibodies",
          "subhead": null,
          "observed_at": "2025-03-31T00:18:12.000Z",
          "evidence": "https://web.archive.org/web/20250331001812/https://www.combotopetherapeutics.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Truly Tumor-Specific antibodies",
      "subhead": null,
      "from": "2025-02-06T18:43:12.000Z",
      "to": "2025-03-31T00:18:12.000Z",
      "captures": 2,
      "evidence": "https://web.archive.org/web/20250331001812/https://www.combotopetherapeutics.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2025-02-06T18:43:12.000Z",
          "to": "2025-03-31T00:18:12.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-11-05T12:52:35.274Z",
      "variants": [
        {
          "headline": "All Cancers - One Solution",
          "subhead": null,
          "observed_at": "2026-03-10T10:08:38.000Z",
          "evidence": "https://web.archive.org/web/20260310100838/https://www.combotopetherapeutics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "All Cancers - One Solution",
          "subhead": null,
          "observed_at": "2026-04-02T15:55:48.000Z",
          "evidence": "https://web.archive.org/web/20260402155548/https://www.combotopetherapeutics.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "All Cancers - One Solution",
          "subhead": null,
          "observed_at": "2026-11-05T12:52:35.274Z",
          "evidence": "https://www.combotopetherapeutics.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "All Cancers - One Solution",
      "subhead": null,
      "from": "2026-03-10T10:08:38.000Z",
      "to": "2026-11-05T12:52:35.274Z",
      "captures": 3,
      "evidence": "https://www.combotopetherapeutics.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "between": {
          "from": "2026-03-10T10:08:38.000Z",
          "to": "2026-11-05T12:52:35.274Z"
        }
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-f1f96e148cb22aed692523e7b107d12b9dd44ae8b69a06a37ef7efe5be234e17:be9b6fd32867a295d53e2f6398d5c3406822d48dad88e8ae3b8647c32f7c4395:headline:3083b727b8e0ecfd",
      "before_evidence": "https://web.archive.org/web/20240905071253/https://www.combotopetherapeutics.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “EGFR, VEGFR, HER2, CD37, FLT3, FGFR, CD19, CD22, CD27, CD25, CD30, CD33, CD38, CD43, Mesothelin, PD-L1, CD44, Podocalyxin (TRA1.60/80), C…” to “Truly Tumor-Specific antibodies”.",
      "between": {
        "from": "2024-09-05T07:12:53.000Z",
        "to": "2025-02-06T18:43:12.000Z"
      },
      "evidence": "https://web.archive.org/web/20250206184312/https://www.combotopetherapeutics.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 2,
      "id": "page-ee39d0efdebd2804571002d4f75e2e4ef72f34d37f395296f88fd2b5130deb38:4132a92b840ef557b2e6d7f4845bb789d54776e40b2755a28746fed8d587e306:headline:9ae8dc1ed1f7b00a",
      "before_evidence": "https://web.archive.org/web/20250331001812/https://www.combotopetherapeutics.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Truly Tumor-Specific antibodies” to “All Cancers - One Solution”.",
      "between": {
        "from": "2025-03-31T00:18:12.000Z",
        "to": "2026-03-10T10:08:38.000Z"
      },
      "evidence": "https://web.archive.org/web/20260310100838/https://www.combotopetherapeutics.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Combotope Therapeutics” company record, https://startuphistory.org/c/combotopetherapeutics.com"
}